In the last trading session, 1.29 million Neumora Therapeutics Inc (NASDAQ:NMRA) shares changed hands as the company’s beta touched 2.48. With the company’s per share price at $1.66 changed hands at -$0.05 or -2.92% during last session, the market valuation stood at $268.19M. NMRA’s last price was a discount, traded about -1165.06% off its 52-week high of $21.00. The share price had its 52-week low at $1.60, which suggests the last value was 3.61% up since then.
Analysts gave the Neumora Therapeutics Inc (NMRA) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.44. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended NMRA as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Neumora Therapeutics Inc’s EPS for the current quarter is expected to be -0.44.
Neumora Therapeutics Inc (NASDAQ:NMRA) trade information
Instantly NMRA was in red as seen at the end of in last trading. With action -4.05%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -84.34%, with the 5-day performance at -4.05% in the red. However, in the 30-day time frame, Neumora Therapeutics Inc (NASDAQ:NMRA) is -21.70% down.
The consensus price target for the stock as assigned by Wall Street analysts is 4, meaning bulls need an upside of 58.5% from its current market value. According to analyst projections, NMRA’s forecast low is 4 with 4 as the target high. To hit the forecast high, the stock’s price needs a -140.96% plunge from its current level, while the stock would need to soar -140.96% for it to hit the projected low.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
The 2025 estimates are for Neumora Therapeutics Inc earnings to increase by 56.61%, but the outlook for the next 5-year period is at 24.81% per year.
NMRA Dividends
Neumora Therapeutics Inc is expected to release its next quarterly earnings report in March.
Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF . With 2.39 shares estimated at $3.97 million under it, the former controlled 1.48% of total outstanding shares. On the other hand, iShares Russell 2000 ETF held about 1.45% of the shares, roughly 2.35 shares worth around $3.9 million.
